Search

Hail to the zebrafish. MSK scientists are using a small fish to answer some big questions about cancer.

… Friday, January 29, 2016 Summary Physician and cell biologist Richard White is using zebrafish to study cancer development. The fish are generating new insights into why only certain cells with genetic mutations turn into cancer and how these cells spread to other parts of the body. Highlights Zebrafish

Read about clinical trial results showing that a liquid biopsy helped select cancer patients for effective immunotherapy treatment.

… Sunday, April 27, 2025 A small pilot study led by researchers at Memorial Sloan Kettering Cancer Center (MSK) has found that a simple blood test can help doctors identify which patients are most likely to benefit from immunotherapy after cancer surgery to remove tumors — potentially preventing the disease

Lea los resultados de ensayos clínicos que demuestran que una biopsia líquida ayudó a seleccionar a pacientes con cáncer para recibir un tratamiento de inmunoterapia eficaz.

… Sunday, April 27, 2025 Un pequeño estudio piloto dirigido por investigadores de Memorial Sloan Kettering Cancer Center (MSK) descubrió que un simple análisis de sangre puede ayudar a los médicos a identificar qué pacientes tienen más probabilidades de beneficiarse de la inmunoterapia después de la cirugía

Five Memorial Sloan Kettering (MSK) faculty were named today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy Class of 2022.

… Tuesday, March 22, 2022 Five Memorial Sloan Kettering (MSK) faculty are among the 33 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2022. Luis Alberto Diaz Jr., MD; Thomas J. Kelly, MD, PhD; Nikola P. Pavletich

Mark H. Bilsky has been named one of the 28 top spine surgeons in North America by Orthopedics This Week.

… Tuesday, July 16, 2013 Mark H. Bilsky has been named one of the 28 top spine surgeons in North America by Orthopedics This Week . The publication surveyed leading spine surgeons and asked them to select the best of their peers. Dr. Bilsky is director of Memorial Sloan Kettering’s multidisciplinary spine

Learn how a family with a young son diagnosed with Ewing sarcoma were helped by the experts at MSK Kids, the pediatric oncology program at Memorial Sloan Kettering Cancer Center.

… Wednesday, September 28, 2022 Gus Frank is seen smiling with his older sister. Gus was treated for Ewing Sarcoma at MSK Kids, the pediatric oncology program at Memorial Sloan Kettering Cancer Center Gus Frank (left) with his older sister Susan. Gus is being cared for by MSK Kids, the pediatric oncology

The FDA has approved nirogacestat (OgsiveoTM), a targeted therapy for desmoid tumors. A recent phase 3 clinical trial found that the drug significantly shrank desmoid tumors in 41% of patients. Desmoid tumors (also known as aggressive fibromatosis) are a rare type of soft tissue tumor.

… Tuesday, November 28, 2023 Update: On November 27, 2023, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be treated with surgery alone. The approval was based on research led by investigators at Memorial Sloan Kettering Cancer Center.

Women on Long Island who don’t have insurance or who are underinsured may be able to take advantage of free mammograms at Memorial Sloan Kettering Cancer Center Commack.

… Tuesday, May 8, 2012 Women on Long Island who don’t have insurance or who are underinsured may be able to take advantage of free mammograms at Memorial Sloan Kettering Cancer Center Commack . The Center has contracted with the New York State Cancer Services Program (CSP) of Western Suffolk County to

American Thyroid Association guidelines endorse close observation as a treatment option for many small papillary thyroid tumors rather than surgery. MSK endocrinologist Michael Tuttle MD discusses why monitoring such cancers is a viable approach.

… Thursday, August 31, 2017 VIDEO | 02:27 Active Monitoring of Papillary Thyroid Cancer American Thyroid Association guidelines endorse close observation as a treatment option for many small papillary thyroid tumors rather than surgery. MSK endocrinologist Michael Tuttle MD discusses why monitoring such

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.

… Thursday, November 21, 2024 On November 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to the drug zanidatamab (Ziihera ® ) to treat advanced and metastatic bile duct cancer (cholangiocarcinoma) and other biliary tract cancers that have high levels of a protein called HER2